126 related articles for article (PubMed ID: 29151933)
41. Combination of CK20 and Ki-67 immunostaining analysis predicts recurrence, progression, and cancer-specific survival in pT1 urothelial bladder cancer.
Bertz S; Otto W; Denzinger S; Wieland WF; Burger M; Stöhr R; Link S; Hofstädter F; Hartmann A
Eur Urol; 2014 Jan; 65(1):218-26. PubMed ID: 22633802
[TBL] [Abstract][Full Text] [Related]
42. Clinical response to induction chemotherapy predicts improved survival outcome in urothelial carcinoma with clinical lymph nodal metastasis treated by consolidative surgery.
Urakami S; Yuasa T; Yamamoto S; Sakura M; Tanaka H; Hayashi T; Uehara S; Inoue Y; Fujii Y; Masuda H; Fukui I; Yonese J
Int J Clin Oncol; 2015 Dec; 20(6):1171-8. PubMed ID: 25953680
[TBL] [Abstract][Full Text] [Related]
43. Expression and predictive value of lymph-specific markers in urothelial carcinoma of the bladder.
von Hardenberg J; Martini T; Knauer A; Ströbel P; Becker A; Herrmann E; Schubert C; Steidler A; Bolenz C
Urol Oncol; 2014 Jan; 32(1):54.e9-17. PubMed ID: 24360666
[TBL] [Abstract][Full Text] [Related]
44. Urothelial carcinoma of the bladder and the upper tract: disparate twins.
Green DA; Rink M; Xylinas E; Matin SF; Stenzl A; Roupret M; Karakiewicz PI; Scherr DS; Shariat SF
J Urol; 2013 Apr; 189(4):1214-21. PubMed ID: 23023150
[TBL] [Abstract][Full Text] [Related]
45. GATA3 immunohistochemistry in urothelial carcinoma of the upper urinary tract as a urothelial marker and a prognosticator.
Inoue S; Mizushima T; Fujita K; Meliti A; Ide H; Yamaguchi S; Fushimi H; Netto GJ; Nonomura N; Miyamoto H
Hum Pathol; 2017 Jun; 64():83-90. PubMed ID: 28428106
[TBL] [Abstract][Full Text] [Related]
46. TBX2 Expression predicts Tumor Recurrence and Adjuvant Chemotherapy Benefits in Gastric Cancer Patients following R0 Resection: a proposed approach for risk stratification.
Lu J; Xu Y; Wang YH; Huang XY; Wu Y; Xie JW; Wang JB; Lin JX; Li P; Zheng CH; Huang AM; Huang CM
J Cancer; 2020; 11(11):3172-3179. PubMed ID: 32231721
[No Abstract] [Full Text] [Related]
47. Does HER2 immunoreactivity provide prognostic information in locally advanced urothelial carcinoma patients receiving adjuvant M-VEC chemotherapy?
Tsai YS; Tzai TS; Chow NH
Urol Int; 2007; 79(3):210-6. PubMed ID: 17940352
[TBL] [Abstract][Full Text] [Related]
48. Sphingosine-1-phosphate receptor 1 (S1PR1) expression in non-muscle invasive urothelial carcinoma: Association with poor clinical outcome and potential therapeutic target.
Go H; Kim PJ; Jeon YK; Cho YM; Kim K; Park BH; Ku JY
Eur J Cancer; 2015 Sep; 51(14):1937-45. PubMed ID: 26238015
[TBL] [Abstract][Full Text] [Related]
49. FGF7 Over Expression is an Independent Prognosticator in Patients with Urothelial Carcinoma of the Upper Urinary Tract and Bladder.
Fan EW; Li CC; Wu WJ; Huang CN; Li WM; Ke HL; Yeh HC; Wu TF; Liang PI; Ma LJ; Li CF
J Urol; 2015 Jul; 194(1):223-9. PubMed ID: 25623741
[TBL] [Abstract][Full Text] [Related]
50. CXCL5 is a potential diagnostic and prognostic marker for bladder cancer patients.
Zhu X; Qiao Y; Liu W; Wang W; Shen H; Lu Y; Hao G; Zheng J; Tian Y
Tumour Biol; 2016 Apr; 37(4):4569-77. PubMed ID: 26503215
[TBL] [Abstract][Full Text] [Related]
51. Adjuvant chemotherapy for invasive urothelial cancer: experience with a methotrexate, vincristine, cisplatin, cyclophosphamide, adriamycin and bleomycin (MVP-CAB) regimen: a preliminary report.
Gohji K; Higuchi A; Maruyama S; Minayoshi K; Fujii A; Itoh N; Hasunuma Y; Tanaka H; Izumi T
Jpn J Clin Oncol; 1993 Oct; 23(5):291-8. PubMed ID: 7693990
[TBL] [Abstract][Full Text] [Related]
52. Risk factors for patients with pelvic lymph node metastases following radical cystectomy with en bloc pelvic lymphadenectomy: concept of lymph node density.
Stein JP; Cai J; Groshen S; Skinner DG
J Urol; 2003 Jul; 170(1):35-41. PubMed ID: 12796639
[TBL] [Abstract][Full Text] [Related]
53. Is Bcl-2 a predictive marker of neoadjuvant chemotherapy response in patients with urothelial bladder cancer undergoing radical cystectomy?
Turker P; Segersten U; Malmström PU; Hemdan T
Scand J Urol; 2019 Feb; 53(1):45-50. PubMed ID: 30806186
[No Abstract] [Full Text] [Related]
54. Thymidylate synthase expression in colorectal cancer: a prognostic and predictive marker of benefit from adjuvant fluorouracil-based chemotherapy.
Edler D; Glimelius B; Hallström M; Jakobsen A; Johnston PG; Magnusson I; Ragnhammar P; Blomgren H
J Clin Oncol; 2002 Apr; 20(7):1721-8. PubMed ID: 11919227
[TBL] [Abstract][Full Text] [Related]
55. Prognostic-factors-based risk-stratification model for invasive urothelial carcinoma of the urinary bladder in Taiwan.
Yang MH; Yen CC; Chen PM; Wang WS; Chang YH; Huang WJ; Fan FS; Chiou TJ; Liu JH; Chen KK
Urology; 2002 Feb; 59(2):232-8; discussion 238-9. PubMed ID: 11834392
[TBL] [Abstract][Full Text] [Related]
56. Expression of bcl-2 protein predicts efficacy of adjuvant treatments in operable node-positive breast cancer.
Gasparini G; Barbareschi M; Doglioni C; Palma PD; Mauri FA; Boracchi P; Bevilacqua P; Caffo O; Morelli L; Verderio P
Clin Cancer Res; 1995 Feb; 1(2):189-98. PubMed ID: 9815973
[TBL] [Abstract][Full Text] [Related]
57. Circulating tumor cells in patients with advanced urothelial carcinoma of the bladder: Association with tumor stage, lymph node metastases, FDG-PET findings, and survival.
Abrahamsson J; Aaltonen K; Engilbertsson H; Liedberg F; Patschan O; Rydén L; Sjödahl G; Gudjonsson S
Urol Oncol; 2017 Oct; 35(10):606.e9-606.e16. PubMed ID: 28676151
[TBL] [Abstract][Full Text] [Related]
58. Perivesical fat invasion in bladder cancer: implications for prognosis comparing pT2b, pT3a and pT3b stages and consequences for adjuvant chemotherapy indications.
Neuzillet Y; Lebret T; Molinie V; Yonneau L; Herve JM; Theodore C; Botto H
BJU Int; 2012 Dec; 110(11):1736-41. PubMed ID: 22998125
[TBL] [Abstract][Full Text] [Related]
59. Tumor-infiltrating CD8+ T cells combined with tumor-associated CD68+ macrophages predict postoperative prognosis and adjuvant chemotherapy benefit in resected gastric cancer.
Lu J; Xu Y; Wu Y; Huang XY; Xie JW; Wang JB; Lin JX; Li P; Zheng CH; Huang AM; Huang CM
BMC Cancer; 2019 Sep; 19(1):920. PubMed ID: 31521128
[TBL] [Abstract][Full Text] [Related]
60. High expression of B7-H3 and CD163 in cancer tissues indicates malignant clinicopathological status and poor prognosis of patients with urothelial cell carcinoma of the bladder.
Xu Z; Wang L; Tian J; Man H; Li P; Shan B
Oncol Lett; 2018 May; 15(5):6519-6526. PubMed ID: 29725402
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
